TerminatedPhase 4

A Study to Assess the Hematopoyetic Response of Anemic Patients With Hematologic Malignancies Treated With Erythropoietin B

Stopped: Due to poor enrollment this study was terminated prematurely.

Venezuela4 participantsStarted 2006-09

Plain-language summary

This study will examine the efficacy, safety and effect on hemoglobin levels, of once weekly subcutaneous injections of epoetin beta (30,000 IU) in anemic participants with non-Hodgkin's lymphoma, chronic lymphocytic leukemia or multiple myeloma. The anticipated study duration is 4 months, and the target sample size is 30 individuals.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Adult participants with a diagnosis of non-Hodgkin's lymphoma, chronic lymphocytic leukemia or multiple myeloma * Anemia at Screening Visit Exclusion Criteria: * Transfusion of red blood cells within 2 months of study drug * Treatment-resistant hypertension * Acute or chronic bleeding (requiring therapy) within 3 months of study drug

What they're measuring

Hemoglobin levels at 16 weeks

Timeframe: 16 Weeks

Trial details

NCT IDNCT02608060

SponsorHoffmann-La Roche

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2007-10

View on ClinicalTrials.gov More Anemia trials